Fasenra: Side Effects & Dosing

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage Patient Counseling Information MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Benralizumab

Indications/Uses

Add-on maintenance treatment in adults from 18 yr w/ severe eosinophilic asthma who have at least 2 exacerbations in the past 12 mth on current standard therapy (high-dose inhaled corticosteroids + long-acting bronchodilators) &/or need for systemic corticosteroid treatment, or eosinophil blood count ≥300 cells/microliter. Add-on treatment in adults w/ relapsing or refractory eosinophilic granulomatosis w/ polyangiitis (EGPA).

Click to view Fasenra detailed prescribing information

Dosage/Direction for Use

SC Asthma 30 mg every 4 wk for 1st 3 doses, then every 8 wk thereafter. EGPA 30 mg every 4 wk.

Click to view Fasenra detailed prescribing information

Overdosage

View Fasenra overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity.

Click to view Fasenra detailed prescribing information

Special Precautions

Discontinue use if hypersensitivity reactions occur. Not to be inj in tender, bruised, erythematous or hardened skin. Not to be used for acute asthma exacerbations. Active organ threatening or life-threatening EGPA manifestations. Parasitic (helminth) infection. Avoid abrupt discontinuation of corticosteroids. Avoid use during pregnancy. Lactation. Childn & adolescents <18 yr.

Click to view Fasenra detailed prescribing information

Use In Pregnancy & Lactation

Click to view Fasenra detailed prescribing information

Adverse Reactions

Headache; pharyngitis; pyrexia, inj site reactions; hypersensitivity reactions.

Click to view Fasenra detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Fasenra detailed prescribing information

Storage

View Fasenra storage conditions for details to ensure optimal shelf-life.

Description

View Fasenra description for details of the chemical structure and excipients (inactive components).

Action

View Fasenra mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antiasthmatic & COPD Preparations

ATC Classification

R03DX10 - benralizumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.

Regulatory Classification

Patient Counseling Information

View Fasenra patient counselling information

Presentation/Packing

Form

Fasenra soln for inj (pre-filled pen) 30 mg/mL

Packing/Price

1's

Form

Fasenra soln for inj (pre-filled syringe) 30 mg/mL

Packing/Price

1's

Fasenra

Manufacturer:

AstraZeneca

Distributor:

Zuellig Pharma